These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8123486)

  • 21. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
    Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
    Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of pS2 protein in breast cancer.
    Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
    Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
    Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
    Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification.
    Bolufer P; Torregrosa MD; Gomez L; Munarriz B; López JA; Asins E; Espinoza S; Vera F; Vazquez C; Guillem V
    Clin Chim Acta; 1996 Mar; 247(1-2):89-103. PubMed ID: 8920230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.
    Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC
    Int J Cancer; 1993 Jun; 54(4):619-23. PubMed ID: 8514453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tumor size on the association between ps2 and cathepsin-d in primary breast-cancer.
    Marsigliante S; Mottaghi A; Muscella A; Ciardo V; Leo G; Storelli C
    Int J Oncol; 1995 Jan; 6(1):69-73. PubMed ID: 21556503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of cathepsin D and pS2 in imprint smears of breast carcinoma.
    Athanassiadou PP; Athanassiades PH; Davaris P; Petrakakou EI; Zerva CI; Kyrkou KA
    Cytopathology; 1998 Aug; 9(4):240-7. PubMed ID: 9710694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical parameters for prognostic evaluation in patients with breast cancer.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
    Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
    Dittadi R; Biganzoli E; Boracchi P; Salbe C; Mione R; Gatti C; Gion M
    Int J Biol Markers; 1998; 13(1):30-41. PubMed ID: 9681297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of pS2 expression of involved lymph nodes in relation to primary breast carcinoma.
    Nichols PH; Ibrahim NB; Padfield CJ; Cawthorn SJ
    Eur J Surg Oncol; 1995 Apr; 21(2):151-4. PubMed ID: 7720888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines.
    Cappelletti V; Fioravanti L; Miodini P; Di Fronzo G
    Tumour Biol; 1996; 17(5):290-8. PubMed ID: 8792855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
    Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
    Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
    Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
    Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoradiometric assay of pS2 protein in breast cancer cytosols.
    Goussard J; Lechevrel C; Roussel G; Cren H; Bera O; Sala M
    Clin Chem; 1991 Oct; 37(10 Pt 1):1759-62. PubMed ID: 1914181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
    Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
    Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.